Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase I/II Study of Avelumab in Pediatric Cancer Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03451825
Recruitment Status : Completed
First Posted : March 2, 2018
Last Update Posted : December 6, 2021
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
EMD Serono ( EMD Serono Research & Development Institute, Inc. )